Title Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Author Dragovich, P S; Webber, S E; Babine, R E; Fuhrman, S A; Patick, A K; Matthews, D A; Reich, S H; Marakovits, J T; Prins, T J; Zhou, R; Tikhe, J; Littlefield, E S; Bleckman, T M; Wallace, M B; Little, T L; Ford, C E; Meador, J W 3rd; Ferre, R A; Brown, E L; Binford, S L; DeLisle, D M; Worland, S T
Journal J Med Chem Publication Year/Month 1998-Jul
PMID 9667971 PMCID -N/A-
Affiliation 1.Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, California 92121, USA.

The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (kobs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50\'s which approach 0.15 microM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (kobs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 microM). A 1.9 A crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.

  • Copyright © 2023
    National Institute of Pathogen Biology, CAMS & PUMC, Bejing, China
    All rights reserved.